Is Electrolytes (sodium, potassium, magnesium) Safe with Tirzepatide (Mounjaro)?
Free · No account · based on published sources including NIH ODS, FDA drug labels, and peer-reviewed literature
Proactively supplement electrolytes if experiencing vomiting, diarrhea, or reduced fluid intake. Monitor for signs of dehydration (dark urine, dizziness, muscle cramps). Patients on antihypertensives or diuretics require closer monitoring. Consult provider if unable to maintain oral hydration.
Why this interaction occurs
Tirzepatide commonly causes nausea, vomiting, and diarrhea, particularly during dose escalation, significantly increasing risk of dehydration and electrolyte depletion (hyponatremia, hypokalemia, hypomagnesemia). Electrolyte supplementation is clinically appropriate in symptomatic patients. Overcorrection with high-sodium electrolyte drinks in patients on renin-angiotensin system agents requires care.
Evidence
Evidence level: strong.
Reported safety data
The FDA’s adverse event reporting system (FAERS) has received 94,106 reports mentioning Tirzepatide (Mounjaro). This reflects reported cases involving the medication in general — not confirmed causation, and not specific to the Tirzepatide (Mounjaro) + supplement combination on this page.
FAERS reports are voluntary and cannot prove that a drug caused an event. Do not use report counts to assess the safety of this specific drug-supplement pair.
Frequently asked questions
Related interactions
All Electrolytes (sodium, potassium, magnesium) interactions → · All Tirzepatide (Mounjaro) interactions →
Already checked this one — check your whole list
Educational only — not medical advice.
Always confirm with your doctor or pharmacist.